{"id":"teriparatide-and-raloxifene","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Leg cramps"},{"rate":null,"effect":"Hot flushes"},{"rate":null,"effect":"Venous thromboembolism risk (raloxifene component)"}]},"_chembl":{"chemblId":"CHEMBL1201549","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teriparatide is a recombinant parathyroid hormone analog that activates PTH1 receptors on osteoblasts to promote bone formation and increase bone mineral density. Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone tissue to inhibit osteoclast-mediated bone resorption. Together, they provide complementary anabolic and anti-resorptive effects for enhanced bone strengthening.","oneSentence":"This combination therapy stimulates bone formation through PTH receptor activation while simultaneously blocking estrogen receptor-mediated bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:45.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01166958","phase":"PHASE4","title":"Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2010-09","conditions":"Osteoporosis","enrollment":26},{"nctId":"NCT01535027","phase":"PHASE4","title":"Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-03","conditions":"Osteoporosis","enrollment":125},{"nctId":"NCT00761332","phase":"","title":"Back Pain in Patients With Severe Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Osteoporosis","enrollment":650},{"nctId":"NCT00191425","phase":"PHASE4","title":"2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-08","conditions":"Osteoporosis, Postmenopausal","enrollment":810},{"nctId":"NCT00079924","phase":"PHASE4","title":"Effects of Teriparatide in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-11","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT00035256","phase":"PHASE4","title":"Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-10","conditions":"Osteoporosis, Postmenopausal","enrollment":330},{"nctId":"NCT00046137","phase":"PHASE3","title":"Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Osteoporosis, Postmenopausal","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forteo","Evista"],"phase":"marketed","status":"active","brandName":"teriparatide and raloxifene","genericName":"teriparatide and raloxifene","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy stimulates bone formation through PTH receptor activation while simultaneously blocking estrogen receptor-mediated bone resorption. Used for Osteoporosis in postmenopausal women.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}